The Road Ahead for Social Security–A Summation of the Situation
The long-term dilemma faced by the Social Security and Medicare Trust Funds is not a self-correcting situation, and most Americans
Read More
Part D/Prescription Drugs
Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs
(By Henry A . Waxman and Bill Corr for ST A T) S uperbugs, disease-causing microbes that have mutated to
Read MoreThe insulin market is heading for a shakeup. But patients may not benefit
(By Rebecca Robbins for ST A T) T he insulin market, dominated by old drugs that have skyrocketed in price
Read MoreWhy Is The News About TB So Bad?
(By Rina Shalkh-Lasko for NPR) Many countries think of TB as a disease of the past and this lack of
Read MoreOpen Enrollment–Time to Re-Check Your Drug Coverage
The annual Medicare Open Enrollment period, which runs through December 7, provides an opportunity to re-examine your Part D drug
Read MoreOpen Enrollment–Some Specific Potential Cost-Savers to Look At
Medicare expert Philip Moeller, in a post today on philly.com, provides a synopsis of several key areas where Medicare participants
Read MoreMedicare Advantage Examined as Open Enrollment Kicks Off
Todd Campbell of Motley Fool takes a look at the changes in store for Medicare Advantage participants in 2017 in
Read MoreA big Alzheimer’s drug trial now wrapping up could offer real hope — or crush it
(By Damian Garde for ST A T) S cientists at Eli Lilly are racing to wrap up a clinical trial
Read MoreOut-of-pocket burden for breast cancer treatment varies across US
(By Kelly Gooch for Becker’s Hospital Review) Breast cancer chemotherapy costs vary widely across the United States, with patients taking
Read MoreDEA opts against ban on herbal supplement kratom
(By Alicia A. Cardwell of Associated Press for ST A T) W ASHINGTON — The Drug Enforcement Administration has reversed
Read More